What if there was a likable person test that we could take to see how other people really view us scientists? How would that work? It turns out that a sense of likability might be more influential in academia than some of us might think, but it’s often problematic too. This came to mind because …
How many academic scientists could pass a likable person test? Read More »
A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall …
Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes …
Where Kimera Labs fits into sphere of exosome companies Read More »
I usually associate NPR with solid journalism so I was scratching my head about a recent puff piece by WHYY on stem cell microneedling. Is this journalism or product promotion? The NPR piece by Maiken Scott doesn’t ask important questions. Scott received stem cell microneedling herself using a product from a company called AnteAGE. How …
WHYY oh WHYY: NPR puff piece on risky stem cell microneedling Read More »
Where do things stand with potential applications of CRISPR and other gene editing technologies in patients? Overall, things are looking very positive. CRISPR human trials This week the third big international human genome editing meeting took place in London. The summit addressed numerous potential clinical applications. It was good to see the agenda included quite …
Weekly reads: big CRISPR mtg, Mesoblast good news, Neuralink spiked Read More »
It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech. There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads …
Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »
Are there endogenous adult heart stem cells that are useful in cardiac disease or can stem cell infusions help ailing hearts? As to the first question, the adult heart does not appear to have meaningful numbers of true stem cells. Further, testing the idea of infusions of stem cells for heart disease has so far been giving …
Heart stem cells trial mostly disappoints but is oversold Read More »
Someday could human brain organoids get to the point of having organized human-like thoughts? Even consciousness? The more time passes, the less likely I think this is. It’s not impossible, but brain organoids have big limitations in that regard. To be clear, I don’t mean brain organoids having some vaguely human brain-like electrical activity. Even monolayers of …
Stem cell research ethics topics: organoid consciousness & embryo models Read More »
Occasionally when I write a post there is an angry reaction to it in the blog comments, which was the case for my recent fact-check of the LifeWave X39 patches. As you can see in that post, I didn’t find convincing data to either back up the claimed stem cell connection. In my opinion, there …
Weekly reads: bat stem cells & viruses, Lineage Cell, He Jiankui visa Read More »
What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a …
Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »